StockCIK 1664710
Keros Therapeutics, Inc. (KROS): Insider Trades and Fund Holdings
In the past 12 months, Keros Therapeutics, Inc. insiders reported 1 open-market purchase worth $10K and 4 sales worth $101K; 1 of the sales were reported as made under a 10b5-1 trading plan.
1Insider buys, 12 months
$10KBought by insiders, 12 months
$101KSold by insiders, 12 months
1Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Aug 20, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 20 | Esther ChoGeneral Counsel | ▼ SELL | $46K |
| Aug 20 | Lorena Raquel LernerChief Scientific Officer | ▼ SELL | $37K |
| Aug 20 | Annita TaniniVP | ▼ SELL | $13K |
| Aug 20 | Charles W. NewtonDirector | ▼ SELL10b5-1 | $6K |
| Aug 19 | Jean Jacques BienaimeDirector | ▲ BUY10b5-1 | $10K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Esther Cho | General Counsel | 0 | $0 | 1 | $46K |
| Lorena Raquel Lerner | Chief Scientific Officer | 0 | $0 | 1 | $37K |
| Annita Tanini | VP | 0 | $0 | 1 | $13K |
| Charles W. Newton | Director | 0 | $0 | 1 | $6K |
| Jean Jacques Bienaime | Director | 1 | $10K | 0 | $0 |
Tracked funds that report KROS
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 359,086 | $3.84M | ▼ −20.8% |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →